Эмпаглифлозин: расширение возможностей терапии сахарного диабета 2 типа


Е.В. Бирюкова

Кафедра эндокринологии и диабетологии ГБОУ ВПО МГМСУ им. А.И. Евдокимова Минздрава России, Москва
Эффективная фармакотерапия сахарного диабета 2 типа остается одной из основных проблем диабетологии. Применение эмпаглифлозина – ингибитора натрий-глюкозного котранспортера 2-го типа (SGLT2), препятствующего реабсорбции глюкозы в проксимальных почечных канальцах и не позволяющего уже отфильтрованной почками глюкозе попадать обратно в кровоток и ускоряющего ее выведение с мочой на различных этапах терапии заболевания, делает достижение длительного контроля гликемии и снижение сердечно-сосудистых рисков вполне реальной целью и имеет определяющее значение для улучшения прогноза сахарного диабета 2 типа.

Литература


  1. Алгоритмы специализированной медицинской помощи больных сахарным диабетом / Под ред. И.И. Дедова, М.В. Шестаковой. 7-й выпуск. М., 2015.
  2. Bloomgarden Z.T. Cardiovascular disease in diabetes. Diabetes Care. 2008;31(6):1260–66.
  3. Boucher J.L., Hurrell D.G. Cardiovascular Disease and Diabetes. Diabetes Spectrum. 2008;21(3):154–55.
  4. Gaede P., Vedel P., Larsen N., Jensen G.V., Parving H.H., Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 2003;348(5):383–93.
  5. Stolar M. Glycemic control and complications in type 2 diabetes mellitus. Am. J. Med. 2010;123(Suppl. 3):3–11.
  6. Emdin C.A., Rahimi K., Neal B., Callender T., Perkovic V., Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015;313:603.
  7. Zoungas S., Chalmers J., Neal B., et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N. Engl. J. Med. 2014;371:1392.
  8. Law M.R., Morris J.K., Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338.
  9. Bailey C.J. The challenge of managing coexistent type 2 diabetes and obesity. BMJ. 2011;342:d1996.
  10. Aronne L.J., Segal R.K. Adiposity and fat distribution outcome measures: assessment and clinical implications. Obes. Res. 2002;10(1):14–21.
  11. Desouza C.V., Bolli G.B., Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care 2010;33(6):1389–94.
  12. Amiel S.A., Dixon T., Mann R., Jameson K. Hypoglycaemia in Type 2 diabetes. Diabet. Med. 2008;25(3):245–54.
  13. Whitmer R.A., Karter A.J., Yaffe K., Quesenberry C.P., Jr., Selby J.V. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA. 2009;301(15):1565–72.
  14. Duckworth W., Abraira C., Moritz T., Reda D., Emanuele N., Reaven P.D., Zieve F.J., Marks J., Davis S.N., Hayward R., Warren S.R., Goldman S., McCarren M., Vitek M.E., Henderson W.G., Huang G.D. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med. 2009;360:129–39.
  15. Barnett A.H., Cradock S., Fisher M., Hall G., Hughes E., Middleton A. Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes. Int. J. Clin. Pract. 2010;64(8):1121–29.
  16. DeFronzo R.A. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773–95.
  17. Chao E.C., Henry R.R. SGLT2 inhibition-A novel strategy for diabetes treatment. Nat. Rev. Drug. Discov. 2010;9(7):551–59.
  18. Ferrannini E. Sodium-glucose transporter-2 inhibition as an antidiabetic therapy. Nephrology Dialysis Transplantation. 2010;25(7):2041–43.
  19. Garber A.J., Abrahamson M.J., Barzilay J.I., Blonde L., Bloomgarden Z.T., Bush M.A., Dagogo-Jack S., Davidson M.B., Einhorn D., Garber J.R., Garvey W.T., Grunberger G., Handelsman Y., Hirsch I.B., Jellinger P.S., McGill J.B., Mechanick J.I., Rosenblit P.D., Umpierrez G., Davidson M.H. AACE/ACE comprehensive diabetes management algorithm. 2015. Endocr. Pract. 2015;21:438–47.
  20. Ehrenkranz J.R., Lewis N.G., Kahn C.R., Roth J. Phlorizin: a review. Diabetes Metab. Rev. 2005;21:31–8.
  21. Gerich J.E. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: Therapeutic implications. Diabetic Medicine. 2010;27(2):136–42.
  22. Wright E.M., Loo D.D., Hirayama B.A. Biology of human sodium glucose transporters. Physiol. Rev. 2011;91(2):733–94.
  23. Hummel C.S., Lu C., Loo D.D.F., Hirayama B.A., Voss A.A., Wright E.M. Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2. Am. J. Physiol. Cell. Physiol. 2011;300(1):14–21.
  24. Ferrannini E., Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat. Rev. Endocrinol. 2012;8(8):495–502.
  25. Santer R., Calado J. Familial renal glucosuria and SGLT2: From a Mendelian trait to a therapeutic target. Clin. J. Am. Soc. Nephrol. 2010;5:133–41.
  26. Wright E.M., Loo D.D.F., Hirayama B.A. Biology of humans Sodium glucose transporters Physiol. Rev. 2011;91:733–94.
  27. Wright E.M. Renal Na(+)-glucose cotransporters. Am. J. Physiol. Renal. Physiol. 2001;280:10–8.
  28. Lee Y.J., Lee Y.J., Han H.J. Regulatory mechanisms of Na(+)/glucose cotransporters in renal proximal tubule cells. Kidney Int. 2007;106(Suppl.):27–35.
  29. Hummel C.S., Lu C., Loo D.D., Hirayama B.A., Voss A.A., Wright E.M. Glucose transport by human renal Na/D-glucose cotransporters SGLT1 and SGLT2. Am. J. Physiol. Cell. Physiol. 2011;300:14–21.
  30. Marsenic O. Glucose control by the kidney: an emerging target in diabetes. Am. J. Kidney Dis. 2009;53(5):875–83.
  31. Vallon V., Sharma K. Sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Curr. Opin. Nephrol. Hypertens. 2010;19(5):425–31.
  32. DeFronzo R.A., Davidson J.A., Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes. Metab. 2012;14(1):5–14.
  33. Del Prato S. Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies. Diabet Med. 2009;26:1185–92.
  34. Grempler R., Thomas L., Eckhardt M., Himmelsbach F., Sauer A., Sharp D.E., et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT2) inhibitor: characterisation and comparison with other SGLT2 inhibitors. Diabetes Obes. Metab. 2012;14(1):650–57.
  35. Martin M.G., Turk E., Lostao M.P., Kerner C., Wright E.M. Defects in Na+/glucose cotransporter (SGLT1) trafficking and function cause glucose-galactose malabsorption. Nature Genetics. 1996;12(2):216–20.
  36. Инструкция по медицинскому применению лекарственного препарата Джардинс. Регистрационное удостоверение ЛП-002735 от 2015.
  37. Hach T., Gerich J.E., Salsali A., Kim G., Hantel S., Woerle H.J., Broedl U.C. Empagliflozin improves glycemic parameters and cardiovascular risk factors in patients with type 2 diabetes (T2DM): pooled data from four pivotal phase III trials. Diabetes. 2013;62(Suppl 1A):69-LB.
  38. Roden M., Weng J., Eilbracht J., Delafont B., Kim G., Woerle H.J., Broedl U.C.; EMPAREG MONO Trial Investigators. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013;1:208–19.
  39. Hаring H.U., Merker L., Seewaldt-Becker E., et al. Empagliflozin as add-on to metformin for 24 weeks improves glycemic control in patients with type 2 diabetes (T2DM)
  40. Kovacs C.S., Seshiah V., Swallow R., Jones R., Rattunde H., Woerle H.J., Broedl U.C. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes. Metab. 2014;16(2):147–58.
  41. Hаring H.U., Merker L., Seewaldt-Becker E., Weimer M., Meinicke T., Woerle H.J., Broedl U.C. Empagliflozin as add-on to metformin plus sul-fonylurea in patients with type 2 diabetes. A 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2013;36(11):3396–404.
  42. Rosenstock J., Jelaska A. Wang F., et al. Empagliflozin as add-on to basal insulin for 78 weeks improves glycemic control with weight loss in insulin-treated type 2 diabetes (T2DM). Diabetes. 2013;62(Suppl. 1):A285.
  43. Roden M., Weng J., Eilbracht J., Delafont B., Kim G., Woerle H.J., Broedl U.C. EMPA-REG MONO trial investigators. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013;1(3):208–19.
  44. Ridderstrаle M, Andersen K.R., Zeller C., Kim G., Woerle H.J., Broedl U.C. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2:691–700.
  45. Rosenstock J., Jelaska A., Wang F., et al. Empagliflozin as add-on to basal insulin for 78 weeks improves glycemic control with weight loss in insulin-treated type 2 diabetes (T2DM). Diabetes. 2013;62(Suppl. 1):A285.
  46. Rosenstock J., Jelaska A. Frappin G., et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled Type 2 Diabetes. Diabetes Care. 2014;37:1815–23.
  47. Hakeem L., Bhattacharyya D., Lafong C., Janjua K., Serhan J., Campbell I. Diversity and complexity of urinary tract infection in diabetes mellitus. Br. J. Diabetes Vasc. Dis. 2009;9:119–25.
  48. Zinman B., Wanner C., Lachin J., Fitchett D., et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N. Engl. J. Med. 2015;373(22):2117–28.


Об авторах / Для корреспонденции


Е.В. Бирюкова – д.м.н., проф., зав. учебной частью кафедры эндокринологии и диабетологии ГБОУ ВПО МГМСУ им. А.И. Евдокимова Минздрава России, Москва; e-mail: lena@obsudim.ru


Похожие статьи


Бионика Медиа